What is CytomX Therapeutics's return on equity?

CytomX Therapeutics (CTMX) reported return on equity of -34.3% in Q1 2026.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

CytomX Therapeutics CTMX Return on equity

Return on equity at other companies

PfizerPFE

10.6%—

AmgenAMGN

101.3%-4.4pp

Janux TherapeuticsJANX

-11.7%+4.1pp

Allogene TherapeuticsALLO

-52.3%-5.7pp

Vor BiopharmaVOR

-125.4%+671pp

Design Therapeutics, Inc.DSGN

-31.3%+19.5pp

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

net income/total stockholders equity=-34.3%

Based on trailing twelve months.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's return on equity?: CytomX Therapeutics (CTMX) reported return on equity of -34.3% in Q1 2026.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.